Product Description
Mechanisms of Action: PPAR-a Agonist, PPAR-g Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Takeda
Company Location: Asia Pacific
Company Founding Year: 1781
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00759720 |
ORIGAMI | P3 |
Terminated |
Type 2 Diabetes |
2004-12-01 |
2024-06-06 |
Primary Endpoints |
|
NCT00762684 |
01-04-TL-559-028 | P3 |
Terminated |
Type 2 Diabetes |
2004-12-01 |
2024-06-06 |
||
NCT00762957 |
01-04-TL-559-029 | P3 |
Terminated |
Type 2 Diabetes |
2004-12-01 |
2024-06-06 |
||
NCT00762112 |
01-03-TL-559-017 | P3 |
Terminated |
Type 2 Diabetes |
2004-12-01 |
2024-06-06 |
||
NCT00763022 |
01-02-TL-559-014 | P3 |
Completed |
Type 2 Diabetes |
2004-12-01 |
2024-06-06 |
||
NCT00762190 |
01-03-TL-559-016 | P3 |
Terminated |
Type 2 Diabetes |
2004-12-01 |
2024-06-06 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|
